The 1 analysts offering 12-month price forecasts for Nabriva Therapeutics PLC have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate represents a +379.04% increase from the last price of 0.84.
The current consensus among 1 polled investment analysts is to Buy stock in Nabriva Therapeutics PLC. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.21
Reporting Date Mar 17
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.